To homepage

Page 3 - Best Melanoma doctors: TOP 73 doctors

Content meets the Bookimed Editorial Policy and is medically reviewed by

Fahad Mawlood

Boaz Gabay

  • New
  • Israel, Tel Aviv, Melanoma Unit Clinica
  • Dr. Boaz Gabay leads the onkodermatology department at the Melanoma Unit of Assuta Hospital, bringing extensive, specialized expertise to skin cancer care.

    • Senior dermatologist at Meir Medical Center's clinic in Kfar Saba
    • Provides expert dermatology consultation at the Beit Levinstein rehabilitation center
    • Completed residency in Dermatology and Venereology at Beilinson Medical Center
    • Trained in medicine at Tel Aviv University's Sackler Faculty of Medicine
  • Read more
Doctor's visit
Price on request
Info

Haim Gutman

  • New
  • Israel, Tel Aviv, Melanoma Unit Clinica
  • Professor Haim Gutman leads the surgical department for oncodermatology at Assuta Hospital and specializes in melanoma treatment.

    • Head of surgical oncology at Rabin Medical Center (Beilinson)
    • Trained in oncologic surgery at MD Anderson, Houston
    • Specializes in melanoma, breast and skin cancer, and bone sarcoma
    • Professor at Tel Aviv University's Sackler Faculty of Medicine
  • Read more
Doctor's visit
Price on request
Info

Kayihan Engin

  • 5 Excellent 1 review
  • 40 years of experience
  • Turkey, Bursa, Medicana Bursa Hospital
  • Prof. Engin brings over 35 years of oncology experience, including a prestigious fellowship at Thomas Jefferson University in Thermoradiotherapy.

    • Former Chairman of Radiation Oncology at Uludağ University
    • Post-doctoral research at the National Cancer Institute, U.S.A.
    • Currently leads Oncological Sciences at Medicana Bursa Hospital
    • Academic Professor with extensive teaching and research background
  • Read more
Doctor's visit
Price on request
Info

Ugur Ekici

  • 2 Good 1 review
  • 25 years of experience
  • Turkey, Istanbul, Medicana Bahcelievler Hospital
  • Assoc. Dr. Ugur Ekici brings over 20 years of surgical expertise, specializing in advanced cancer surgery techniques at Medicana Bahcelievler Hospital.

    • Specialized in cancer surgery with extensive laparoscopic experience
    • Published research in international medical journals
    • Completed rigorous training at Şişli Etfal Hospital's General Surgery Clinic
  • Read more
Doctor's visit
Price on request
Info

Shaunak Valame

  • New
  • 9 years of experience
  • accreditation:
  • India, Nashik, HCG Manavata Cancer Centre
  • Specializes in melanoma with a focus on targeted therapies and molecular research – presenting research at the American Society of Clinical Oncology.

    • Completed DNB in Medical Oncology from Indraprastha Apollo Hospital
    • Delivered lectures at International Winter School of Oncology
    • Published research on stomach cancer at ASCO symposium
    • Experienced registrar at Jawaharlal Nehru Cancer Hospital and Research Centre
  • Read more
Immunotherapy with Keytruda (Pembolizumab)
$3,200 - $4,000
Info

Escarlata Lopez

  • New
  • 33 years of experience
  • Spain, Madrid, GenesisCare Clinics
Doctor's visit
Price on request
Info

Shruti Kate

  • New
  • 14 years of experience
  • India, Nashik, HCG Manavata Cancer Centre
  • Dr. Shruti Kate specializes in treating advanced cancers with immunotherapy and metronomic therapy. She trained at Tata Memorial Hospital, a leading cancer center.

    • Member of ASCO, ESMO, and other top oncological societies
    • Presented research on lung cancer at the World Conference on Lung Cancer
    • Recipient of a travel award from India for WCLC 2018
    • Expertise in lung, breast, gynecological, and genitourinary cancers
  • Read more
Immunotherapy with Keytruda (Pembolizumab)
$3,200 - $4,000
Info

Ravindra Tandale

  • New
  • 16 years of experience
  • India, Nashik, HCG Manavata Cancer Centre
Immunotherapy with Keytruda (Pembolizumab)
$3,200 - $4,000
Info

Chaitainya Borde

  • New
  • 10 years of experience
  • India, Nashik, HCG Manavata Cancer Centre
  • Handled more than 30,000 PET scans and 1,000 thyroid cancer patients – Dr. Borde specializes in advanced nuclear medicine at HCG Manavata Cancer Centre.

    • 12 years of experience in nuclear medicine
    • Proficient in radioiodine and Lu-177 RN therapies
    • Skilled in all types of nuclear scans, including PET-CT
    • Published papers in various medical journals
  • Read more
Immunotherapy with Keytruda (Pembolizumab)
$3,200 - $4,000
Info

Sridhar P.S.

  • New
  • 29 years of experience
  • India, Nashik, HCG Manavata Cancer Centre
  • Dr. Sridhar P.S. specializes in melanoma treatment at HCG Manavata Cancer Centre, with extensive training in radiotherapy.

    • Diplomate of National Board in radiotherapy
    • Member of the Association of Radiation Oncology of India
    • Part of the Bangalore Oncology Group
    • Specializes in neuro-oncology as part of the Society for Neuro-Oncology
  • Read more
Immunotherapy with Keytruda (Pembolizumab)
$3,200 - $4,000
Info

Phd Viola Fox

  • 4.7 Excellent 60 reviews
  • 13 years of experience
  • Germany, Solingen, Medical Center in Solingen
  • Specializes in melanoma treatment with immunotherapy and targeted therapies – Phd Viola Fox leads the Haematology, Oncology, and Palliative Care Clinic at BKZ Solingen.

    • 15+ years of experience in oncology and haematology
    • Expert in molecular diagnostics for personalized treatment plans
    • Active researcher in molecular biology for innovative cancer therapies
    • Member of German and American oncology societies
  • Read more
Doctor's visit
Price on request
Info

Dr. Sezer Saglam

  • 5 Excellent 50 reviews
  • 28 years of experience
  • accreditations:
  • Turkey, Istanbul, Istanbul Florence Nightingale Hospital
  • Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

    Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

  • Read more
Doctor's visit
Price on request
Info

Muhammed Gomec

  • 5 Excellent 1 review
  • 16 years of experience
  • Turkey, Sivas, Medicana Sivas Hospital
Doctor's visit
Price on request
Info

Hamza Ugur Bozbey

  • New
  • 11 years of experience
  • Turkey, Istanbul, Uniqacare Clinic
Doctor's visit
Price on request
Info

Emrah Eraslan

  • New
  • 20 years of experience
  • Turkey, Ankara, Private Koru Ankara Hospital
  • Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:

    Breast Cancer

    Prostate Cancer

    Lung Cancer

    Colorectal Cancer

    Stomach Cancer

    Ovarian Cancer

  • Read more
Doctor's visit
Price on request
Info

Seyda Gunduz

  • 4.4 Good 17 reviews
  • 15 years of experience
  • Turkey, Istanbul, Istinye University Liv Hospital Bahcesehir
Doctor's visit
Price on request
Info

Alandag Celal

  • 5 Excellent 1 review
  • 16 years of experience
  • Turkey, Sivas, Medicana Sivas Hospital
Doctor's visit
Price on request
Info

Nail Paksoy

  • 4.5 Good 2 reviews
  • 14 years of experience
  • accreditation:
  • Turkey, Istanbul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Read more
Wide excision of melanoma
$4,000 - $6,000
Melanoma surgery
$5,000 - $10,000
Info

Ismail Ozdemir

  • 5 Excellent 1 review
  • 45 years of experience
  • Turkey, İzmir, Ento Surgical Medical Center
  • Dr. Ismail Ozdemir specializes in Ear, Nose, Throat, and Head and Neck Surgery with decades of experience in leading hospitals.

    • Graduated from Hacettepe University Eskisehir Medical Faculty in 1980
    • Completed career education at Hacettepe University Medical Center
    • Held leadership roles at Izmir Atatürk Education and Research Hospital
    • Former head of ENT at Namik Kemal University Medical Faculty
  • Read more
Doctor's visit
Price on request
Info

Eslie Perez

  • New
  • 11 years of experience
  • Mexico, Puerto Vallarta, Holistic Bio Spa®
  • Specializes in dermatological procedures with extensive experience in laser treatments and minimally invasive techniques.

    • Head of Teaching at Puerto Vallarta Regional Hospital
    • Medical Assistant in dermatology clinic for 5 years
    • Certified in Biomagnetism by Higher Institute of Biomagnetism
    • Experience with fractional laser and IPL for facial rejuvenation
  • Read more
Surgeon's portfolio
Doctor's visit
Price on request
Info

Bookimed Insights: Top Doctors for Melanoma Treatment

Bookimed has coordinated 1743 patient requests for Melanoma treatment, working with 73 specialists worldwide. The doctors in this table consistently stand out for their credentials and expertise in addressing specific patient needs. All information comes from actual patient cases and treatment offers created by our partner clinics.
DoctorexperienceGood Fit ForWhat Sets Them ApartClinic & LocationConsultation
2025 years of experienceMelanoma and onkodermatologyLeads the dedicated Melanoma Unit at Assuta Hospital, focusing specifically on skin cancer within a top-tier onkodermatology department.
Israel
Price on request
2025 years of experienceMelanoma and skin cancer surgeryLeads oncodermatology at Assuta Hospital and surgical oncology at Rabin Medical Center. Trained at MD Anderson – specializes in complex melanoma cases.
Israel
Price on request
40 years of experienceComplex melanoma casesSpecialized in Thermoradiotherapy with U.S. fellowship training. Former department chairman with decades of academic and clinical leadership in oncology.
Turkey
Price on request
25 years of experienceAdvanced cancer surgery casesSpecializes in advanced laparoscopic cancer surgery techniques with 20+ years' experience. Published researcher in international medical journals.
Turkey
Price on request
9 years of experienceTargeted therapies for melanomaFocused on molecular basis of cancer – presented research at ASCO and pursues targeted therapies. Academically active and research-oriented.
India
Price on request
14 years of experienceAdvanced melanoma immunotherapySpecializes in immunotherapy for advanced cancers – presented at the World Conference on Lung Cancer. Trained at Tata Memorial Hospital.
India
Price on request
10 years of experienceAdvanced nuclear medicineSpecializes in nuclear medicine with extensive PET-CT experience. Proficient in radioiodine and Lu-177 therapies. Published researcher in the field.
India
Price on request
29 years of experienceMelanoma radiotherapySpecializes in melanoma with advanced radiotherapy training. Active in neuro-oncology and member of key oncology associations like Bangalore Oncology Group.
India
Price on request
13 years of experienceImmunotherapy and targeted therapyLeads a certified cancer center with a focus on molecular diagnostics. Active in research to develop innovative treatments for melanoma.
Germany
Price on request
45 years of experienceHead and neck surgerySpecializes in ENT and head-neck surgery with extensive academic and hospital leadership roles. Former head of ENT at Namik Kemal University.
Turkey
Price on request